健择在难治性非霍奇金淋巴瘤治疗中的应用研究

Clinical Applications of Gemcitabine in the Treatment of Refractory Non-Hodgkin s Lymphoma

摘要: 目的　观察健择联合顺铂、强的松治疗难治性非霍奇金淋巴瘤的近期疗效。方法　健择10 0 0mg/m2, 静滴, d1,8;顺铂 2 5mg/m2, 静滴, d1～ 3 ;强的松 6 0mg/m2, 口服, d1～ 5。以 3～ 4周为 1周期, 每例患者至少连用 3个周期。结果　全组 10例病人中, CR 2例, PR 5例, 总有效率 70 %。 4例具有B类症状患者中, 2例症状消失, 1例明显改善, 1例无改善。毒副反应主要是轻度的胃肠道反应和少数患者出现Ⅲ级以上骨髓抑制。结论　健择联合顺铂、强的松治疗难治性非霍奇金淋巴瘤有较好的近期疗效, 其毒副反应可耐受, 是值得临床进一步验证的补救性化疗方案。

Abstract: Objective To study the effects of gemcitabine combined with cisplatine and predinisone in the treatment of refractory Non-Hodgkin s Lymphoma(NHL). Methods 10 patients with refractory NHL were treated with gemcitabine, 1000mg/m 2,VD,d_ 1,8;cisplatine, 25mg/m 2,VD,d_ 1～3; and prednisone, 60mg/m 2, po,d_ 1～5; every cycle(3～4 weeks). All patients received at least three cycles of chemotherapy. Results There were 2 cases of CR, 5 cases of PR and the total response rate was 70%. Of the 4 patients who suffe...